enGene Therapeutics Inc 10-K for FY2023
enGene Therapeutics Inc. (ENGN)
10-K
2024-01-29
For: 2023-10-31
View Original
Added on
April 10, 2026
About this 10-K
enGene Therapeutics Inc filed this 10-K on January 29, 2024, covering the fiscal year ended October 31, 2023 (FY2023).
Headline figures
Fiscal year ended October 31, 2023, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Net loss
- $99.92M
- compared with a net loss of $24.46M a year earlier
- Diluted EPS
- $151.22
- up 241.4% from $44.30 a year earlier